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Abstract: Current formulations for acute tryptophan (Trp) or tyrosine (Tyr) plus phenylalanine (Phe) depletion and loading cause 
undesirable decreases in ratios of Trp or Tyr + Phe to competing amino acids (CAA), thus undermining the specificities of these tests. 
Branched-chain amino acids (BCAA) cause these unintended decreases, and lowering their content in a new balanced control formula-
tion in the present study led to normalization of all ratios. Four groups (n = 12 each) of adults each received one of four 50 g control for-
mulations, with 0% (traditional), 20%, 30%, or 40% less of the BCAA. The free and total [Trp]/[CAA] and [Phe + Tyr]/[BCAA + Trp] 
ratios all decreased significantly during the first 5 h following the traditional formulation, but were fully normalized by the formulation 
containing 40% less of the BCAA. We recommend the latter as a balanced control formulation and propose adjustments in the depletion 
and loading formulations to enhance their specificities for 5-HT and the catecholamines.
Keywords: acute tryptophan depletion and loading, acute tyrosine depletion test, amino acid formulations, branched-chain amino acids, 
catecholamines, competing amino acids, dopamine, isoleucine, leucine, noradrenaline, phenylalanine, tryptophan, tyrosine, valineBadawy et al
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Introduction
The acute tryptophan (Trp) (ATD) and tyrosine (Tyr) 
plus phenylalanine (Phe) (ATPD) depletion and load-
ing (ATL, ATPL) tests1,2 are powerful tools for study-
ing the role of the cerebral monoamines serotonin 
(5-hydroxytryptamine  or  5-HT),  dopamine  (DA) 
and  noradrenaline  (NA)  in  healthy  volunteers  and 
in those with psychiatric and behavioural disorders. 
In the preceding article,3 we described the general 
mechanisms of action of these depletion and load-
ing tests, one of which is competition for transport 
across the blood-brain barrier between six competing 
amino acids (CAA), namely Trp, Tyr and Phe, plus 
the 3 branched-chain amino acids (BCAA) Val, Leu 
and Ile. We3 also reviewed the many applications of 
these tests and the biochemical mechanisms underpin-
ning their use, and presented evidence for their poor 
specificities for the intended monoamine changes. In 
the present paper, we have addressed the question of 
specificity experimentally using the control formula-
tion as a starting point, to be followed subsequently 
by applying the outcome to the depletion and loading 
formulations, because the control formulation: (1) is 
common to both the ATD and ATPD tests and their 
loading counterparts, as it shares the same amino acid 
components, except when depletion and loading are 
required;  (2)  suffers  undesirable  decreases  in  both 
the [Trp]/[CAA] and the [Phe + Tyr]/[BCAA + Trp] 
ratios, which predict the rates of entry into the brain of 
Trp and Tyr + Phe respectively. It is, however impor-
tant first to describe briefly here evidence for the poor 
specificity of the different formulations in current use 
and the rationale for the present study.
In their review, Reilly et al (1997)4 noted that 
many investigators using the ATD or its control for-
mulation did not determine the free or total [Trp]/
[CAA] ratio and only a few measured peripheral 
levels of Tyr or its ratio to large neutral amino acids. 
While it must be assumed that the [Trp]/[CAA] ratio 
is decreased after ATD and increased after ATL, a 
decrease in this ratio has also been observed with 
a  100  g  “balanced”  control  formulation  for ATD 
containing the usual 2.3 g of Trp.5 This ratio was 
also decreased in the control formulation if the Trp 
content  was  increased  to  3.0  g,6  whereas  further 
increases to 4.1 g7 or 4.6 g8 of Trp led to elevations 
of this ratio. From data extracted from our previous 
detailed  pharmacokinetic  and  behavioural  study9 
comparing a 50 g with the traditional 100 g dose of 
the amino acid   formulations for the ATD and ATL 
tests, we reported10 that intake of 50 g of the control 
  formulation containing 1.15 g of Trp decreased the 
[Free Trp]/[CAA] ratio maximally by 61%.
We also found10 that the [Phe + Tyr]/[BCAA + Trp] 
ratio was decreased in the ATD, ATL and also in the 
control formulation by about 50%. Broadly similar 
decreases (40%–60%) in this latter ratio have been 
reported previously11–13 in control formulations used 
in the ATPD test, which are essentially similar to the 
control formulation for the ATD or ATL test as far as 
the CAA competitors are concerned. Furthermore, in 
the ATPD test, both the control and the Phe plus Tyr-
deficient formulations are associated with decreases 
in the [Trp]/[CAA] ratio, of 30%–62% with the con-
trol formulation, and of 34%–96% with the depleting 
formulation.2,11,13–16
As discussed in the preceding article,3 the reason 
for the above undesirable decreases in the [Phe + Tyr]/
[BCAA + Trp] and [Trp]/[CAA] ratios in the control 
or the corresponding relevant depletion (or loading) 
formulations is the relatively larger contents of the 
three BCAA (i.e. Leu, Val and Ile), compared with 
those of Phe, Tyr and/or Trp, in the original Trp1 or 
Tyr + Phe2 formulation [see the traditional control for-
mulation (F0) in Table 2]. The above ratio decreases 
suggest that 5-HT, DA and/or possibly NA synthesis 
could be inhibited by the control formulation for the 
ATD and ATPD tests and also by the corresponding 
depletion or loading formulation, an effect that could 
confound interpretation of behavioural changes (or 
lack of them).
The rationale of the present study is that, based 
on the above observations and on theoretical graphs 
designed to maintain normal Trp and Tyr ratios under 
the depletion, loading, or balanced condition, if the 
contents of the [BCAA] or of [Phe + Tyr] were to be 
altered independently, we proposed10 two strategies 
for normalizing these ratios: (1) decreasing the con-
tents of the three BCAA by ∼ 30%; or (2) increasing 
those of Phe and Tyr by ∼ 50%. Of these, the first is 
the preferred strategy, because it avoids the metabolic 
consequences of Phe and Tyr loading likely to be asso-
ciated with the latter strategy, because, if adopted, it 
could contribute to a further lowering of both the free 
and total [Trp]/[CAA] ratios in the control formula-
tion. A third strategy, applicable only to the control Formulations for tryptophan or tyrosine plus phenylalanine depletion
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formulation, is to increase the Trp content.17   However, 
while this may improve the [Trp]/[CAA] ratio, it can 
only further decrease the [Phe + Tyr]/[BCAA + Trp] 
ratio and thus lead to a greater depletion of brain cate-
cholamines. In the present paper, we report the results 
of experiments testing the first of these strategies with 
regard to the control formulation, successfully dem-
onstrate the normalization of the Trp and Tyr + Phe 
ratios by decreasing the contents of the BCAA in the 
control formulation, and propose new common for-
mulations more specific for manipulations of central 
5-HT  and  catecholamine  synthesis. A  summary  of 
part of this work has appeared in abstract form.18
Materials and Methods
Participants
Participants  were  recruited  through  various  media 
advertisements and those who met the necessary cri-
teria by telephone interview were invited to undergo 
a rigorous psychiatric and medical screen. Those who 
passed the screening tests were invited to participate. 
Screening involved the Structured Clinical Interview 
for DSM-IV,19 Axis I Disorders, a health history and 
physical examination, urine drug screen (for amphet-
amines, barbiturates, benzodiazepines, cannabinoids, 
cocaine  metabolites  and  opiates),  breath  alcohol 
screen, and urine pregnancy screen. Exclusion criteria 
included: (1) past or present psychiatric diagnosis; (2) 
past or present medical condition that would interfere 
with results, including head injury causing loss of 
consciousness for .20 min; all medical screens were 
stringent and, if there was any question or doubt, the 
person was excluded; (3) smoking .1 packet of ciga-
rettes per day; (4) positive breath alcohol; (5) positive 
urine drug or pregnancy screen. In total, 48 partici-
pants were recruited and were randomly assigned to 
one of four groups (n = 12 each). The participants 
gave their written informed consents to participate 
in the study, which was approved by the Institutional 
Review  Board  of  Wake  Forest  University  Health 
Sciences  Center,  NC,  USA  (where  the  study  was 
performed)  and  conducted  in  accordance  with  the 
Declaration of Helsinki.
Design
Participants between groups were matched for age, 
gender, and ethnicity (Table 1). A between-, rather 
than a within-group design was chosen for formula 
administration  to  reduce  participant  burden  and 
  attrition, and, as can be seen in the Results section, 
significant baseline differences were observed in only 
5 out of 60 biochemical parameters across the 4 study 
groups. Although female subjects were included, the 
phase  of  the  menstrual  cycle  was  not  considered, 
which may represent a weakness of this study (see also 
the Discussion section). However, all 4 study groups 
included female subjects in roughly similar numbers, 
and analysis of the vital biochemical parameters in 
Table 3 revealed no significant gender differences. In 
view of this and of these small numbers, any likely 
effect on results will have been equally distributed.
general procedures
Participants were instructed to fast overnight, which 
was verified by self-report upon arrival at the labo-
ratory at 07.30. Expired-air and urine samples were 
collected and tested for alcohol and metabolites of 
illicit drugs, as stated above. Participants were then 
transported from the laboratory to the General Clinical 
Research Center (GCRC) where an intravenous cath-
eter was inserted into an antecubital vein at 08.15. The 
viability of the catheter was maintained throughout 
the day with a slow, steady saline drip. The study was 
double blind. To standardize drink administration and 
maintain its double blind, a GCRC staff member mixed 
each of the amino-acid formulations with 8 oz of cold 
Table 1. Participant characteristics.
Formulation
Parameter F0 F1 F2 F3
N 12 12 12 12
Male/Female 5/7 6/6 6/6 6/6
caucasian/African American 6/6 6/6 6/6 7/5
Age range (years) 21–36 21–38 21–36 18–38
Mean age ± sD 27.3 ± 5.4 26.3 ± 3.9 26.3 ± 5.3 26.7 ± 5.9Badawy et al
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water, 1 packet of Sweet and Low® sugar substitute, 
and flavoured the beverage with 1/8th teaspoon each 
of  raspberry  and  lemonade  Kool-Aid.®  Because  of 
their aversive taste and odour, cysteine and methionine 
were administered in capsules (2 each) and   swallowed 
with water. Neither the study staff members nor the 
participants were aware of the contents of the drinks 
being administered. Between 09.00 and 09.15, a study 
staff member administered one of the four 50-g drinks 
containing  the  traditional  amounts  of  the  balanced 
control formulation (F0), or a formulation contain-
ing 20% less (F1), 30% less (F2), or 40% less (F3) 
of the BCAA Leu, Val, and Ile. The differences were 
made up by proportionate (and hence small) increases 
(i.e. 20%, 30%, or 40% increases) divided proportion-
ately across all the other amino acids, as can be seen 
in Table 2. The contents of Trp, Phe and Tyr of the 
experimental formulations remained the same as those 
of the traditional formulation (F0). Blood sampling 
was conducted by research nurses. A fasting   baseline 
blood sample (10 ml) was drawn at 08.45, prior to 
drink administration. Research nurses withdrew 10 ml 
blood samples at 1-hour intervals for 7 h after par-
ticipants consumed the amino-acid drink. During all 
procedures, participants relaxed in a reclining posi-
tion and were allowed to read or watch television, but 
were not allowed to sleep. Participants continued fast-
ing, receiving water only, until a Trp balanced meal 
was provided by the GCRC at 16.30. Fasting elimi-
nates the short-term effects of food intake on plasma 
amino  acids. Although  levels  of  the  plasma  amino 
acids exhibit diurnal variations, the ratios of Trp, Tyr 
and Phe to the other CAA are not altered between the 
morning and afternoon hours (for references, see20), 
i.e. during the entire 7 h time-course of our study.
Biochemical laboratory procedures
Plasma  was  isolated  in  EDTA  tubes  and  frozen  at 
–80 °C until transported in the frozen state to Cardiff, 
Wales  for  analysis.  Ultrafiltrates  (at  least  0.3  ml 
each) were prepared from fresh plasma, before freez-
ing,  using  the Amicon  (Millipore)  MPS-1  partition 
microassembly  (Amicon  Bioseparations,  Beverly, 
MA, USA; Millipore, Burlington, MA, USA) and were 
then stored along with the plasmas. Plasma free [Trp] 
was determined by a modification21 of a standard fluo-
rimetric procedure22 as described in detail previously23 
in  duplicate  0.1  ml  portions  of  ultrafiltrates.  Total 
[Trp] and those of the 5 Trp competitors (CAA) were 
determined  by  our  recently  developed  rapid  gas-
chromatographic method24 using norvaline as internal 
standard.  GC  data  processing  and  handling  were 
performed by the associated Total Chrome software 
(Perkin-Elmer) and results did not require correction, 
as recovery of amino acids was excellent (∼100%).24 
Plasma free [Trp] was determined more economically 
by  fluorimetry  in  preference  to  GC,  as  the    former 
method can process ∼ 60 samples within ∼ 2 h, as 
opposed to .8 h by GC and both methods show a 
very high correlation (r = 0.9774).24
statistical analysis
Results (expressed in µM or as ratios) were analysed 
statistically mainly by one-way analysis of variance 
(ANOVA) for between- and within-group differences, 
and,  additionally  for  within-group  differences  (time 
factor versus baseline values), by paired t-tests, using 
Sigma Plot (Systat, UK) version 11, with which graph-
ics  were  prepared.  For  multiple  group  comparisons 
using this programme, the Holm-Sidak test is recom-
mended as the first line procedure, as it is more powerful 
Table 2. composition of the four amino-acid formulations.
Amino acids Formulation 
(% change in the three BCAA)
F0 
(0%)
F1 
(-20%)
F2 
(-30%)
F3 
(-40%)
Tryptophan 1.15 1.15 1.15 1.15
Phenylalanine 2.85 2.85 2.85 2.85
Tyrosine 3.45 3.45 3.45 3.45
Leucine* 6.75 5.40 4.73 4.05
Valine* 4.55 3.64 3.19 2.73
Isoleucine* 4.00 3.20 2.80 2.40
Alanine† 2.75 3.05 3.19 3.34
Arginine† 2.45 2.71 2.84 2.98
cysteine† 1.35 1.49 1.57 1.64
glycine† 1.60 1.77 1.86 1.94
histidine† 1.60 1.77 1.86 1.94
Lysine† 4.45 4.93 5.17 5.41
Methionine† 1.50 1.66 1.74 1.82
Proline† 6.10 6.75 7.08 7.41
serine† 3.45 3.82 4.01 4.19
Threonine† 3.25 3.60 3.77 3.95
Total 51.25 51.24 51.25 51.25
Notes: *Branched-chain amino acids, the decreases in which were 
compensated for proportionately across the remaining amino acids. 
†In each formulation.Formulations for tryptophan or tyrosine plus phenylalanine depletion
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than the Tukey or Benferroni tests and can be used for 
both pairwise comparisons and those versus a control 
group. Because there were two outliers in the F1 group 
(see the Results section), the number of subjects in this 
group was only 10. Where group sizes differ, Dunn’s 
test is used for pairwise comparisons and those versus 
a control group. Where the data failed the normality 
(Shapiro-Wilk) test, Kruskal-Wallis one-way ANOVA 
on ranks was performed. A two-tailed level of signifi-
cance (P  ) was set at 0.05. All significant within- group 
differences from baseline are indicated by an asterisk 
on the left-hand-side of each column value at the 1–7 h 
time points in Table 3 and by an asterisk above the rel-
evant graph points in Fig. 1. Significant group differ-
ences between values in the F0 group on the one hand 
and those in the F1, F2 or F3 group on the other at the 
0–7 h time-intervals are indicated by various symbols 
on the right-hand-side of the relevant column values 
in Table 3. Other comparisons of group differences 
between the F1, F2 and F3 groups are described in the 
relevant parts of the text of the Results section.
Results
The amino acid drinks were all tolerable, with no 
reported  side  effects  other  than  expected:  namely 
drowsiness, a slight nausea that could also be attrib-
uted to fasting, and no emesis. There was no attrition 
in any group following drink consumption.
The full set of biochemical results is presented in 
Table 3 as a reference guide to enable investigators 
to assess likely changes in the various parameters of 
interest following consumption of amino acid formu-
lations with varying composition of the BCAA. The 
significant changes in each of the 15 parameters listed 
with time from baseline are expressed by an aster-
isk on the left-hand-side of each column value (from 
1–7 h) and will not be described further here, except 
for the ratios. Results in the F1 group are given as 
means of only 10 subjects, as there were two outli-
ers (subjects numbers 1 and 2), who showed greatly 
elevated baseline values for the 5 Trp competitors 
(CAA) (by 97%–129%) than the average of the other 
10 subjects), but a smaller elevation of baseline total 
[Trp]  (of  58%–60%),  suggestive  of  having  had  a 
high protein meal before the test. In this section, the 
effects of decreasing the contents of the 3 BCAA on 
their plasma concentrations and on those of the other 
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Figure 1. Time-course of changes in the ratios of free tryptophan (Trp) 
to competing amino acids (cAA; panel a), total Trp to cAA (panel b), 
and phenylalanine (Phe) plus tyrosine (Tyr) to the BcAA plus total Trp 
(panel c) as a function of time after intake of 50 g of the original balanced-
control formulation (F0) and the formulation (F3) with 40% less of the 
branched-chain amino acids (isoleucine, leucine, and valine; BcAA). In 
this latter formulation, the contents of Phe, Tyr and Trp were held con-
stant. error bars represent seM for n = 12 participants per group, except 
for F1, where a mean of 10 subjects is presented. The asterisk denotes 
a significant difference from the baseline value (P = 0.05–0.0009). For 
other statistical comparisons, see Table 3 and the relevant text in the 
Results section.Badawy et al
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3 competitors will be described first, to be followed 
by a description of changes in the ratios.
effects of decreasing the contents of the 
BcAA on their plasma concentrations
As shown in Table 3, there was the generally expected 
dose-dependent decrease in the sum of plasma concen-
trations of Val, Leu, and Ile from the traditional formu-
lation (F0) with decreasing contents of the 3 BCAA 
(–20%, –30% and –40% in the F1, F2 and F3 groups 
respectively). At baseline, [BCAA] did not differ sig-
nificantly between any of the 4 groups (P = 0.183).
The data in Table 3 show that, following consump-
tion of the formulation drinks, levels of BCAA did 
not differ significantly at any of the 7 hourly time 
points between the participants who consumed the 
traditional formulation (F0) and those who consumed 
the F1 formulation. By contrast, compared with the 
F0 formulation, [BCAA] were significantly lower in 
subjects who consumed the F2 or F3 at 1, 2, 3 and 
5 h after drink consumption (P = 0.034–0.001). Com-
pared  with  [BCAA]  in  the  F1  group,  significantly 
lower values were observed in the F2 and F3 groups 
at 3 h (P = 0.017–0.002) after formula consumption. 
There  were  no  significant  differences  in  [BCAA] 
between F2 and F3 participants at any time interval 
after formula intake.
An inspection of the data in Table 3 for the individ-
ual BCAA shows similar dose-dependent decreases 
in their concentrations as for their sum, with decreas-
ing content of BCAA in the formulations. For Val, 
Leu and Ile, baseline values did not differ signifi-
cantly between groups. For Val, there were signifi-
cant differences between F1 and F3 at 1, 2, 3 and 4 h 
(P = 0.037–0.005). With Leu, significant differences 
were observed between F1 and F2 at 4 h (P = 0.001), 
F1 and F3 at 3, 4 and 6 h (P = 0.049–0.001), and F2 
and F3 at 3 and 4 h (P = 0.006–0.001). Finally, with 
Ile, only the difference between F1 and F3 at 3 h was 
significant (P = 0.009).
effects of decreasing the contents  
of branched-chain amino acids  
on plasma tryptophan, phenylalanine  
and tyrosine concentrations
As the contents of Trp, Phe and Tyr were not altered 
in  the  different  formulations,  it  was  assumed  that Badawy et al
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their plasma concentration-time profiles should be 
similar in all 4 groups of participants. The data in 
Table 3 show that this was largely the case. With 
both free and total [Trp], no significant group dif-
ferences were observed, except those in [free Trp] 
at  baseline  between  the  F0  and  the  other  groups 
(P  =  0.05).  Because  of  the  absence  of  significant 
group differences in free and total [Trp], the per-
centage free Trp (an expression of Trp binding to 
albumin)  showed  no  significant  group  differences 
before or during the 7 h time course of the experi-
ment (data not shown). With Phe and Tyr, their sum 
was unexpectedly higher in the F1, compared with 
the other three groups. The only significant differ-
ences were observed with the F1 group, when com-
pared with F0 at 2–4 h (P = 0.002–0.003), with F2 
at 2 and 4 h (P = 0.009) and with F3 at 2 and 4 h 
(P = 0.071–0.038). As the results in Table 3 show, 
the higher [Phe + Tyr] in the F1 group was due to the 
greater rises in both [Phe] and [Tyr], with the rises 
in [Phe] immediately preceding those in [Tyr], as 
would be expected in a precursor-product relation-
ship. Plasma [Phe + Tyr] values did not differ among 
any of the 4 formulation groups at baseline. There 
were also no differences found between the F0 and 
F2, the F0 and F3, and the F2 and F3 formulations at 
any of the 7 hourly time intervals after consumption 
of the drinks (P . 0.10).
effects of decreasing the contents  
of branched-chain amino acids  
on the sum of their concentrations plus 
tryptophan ([BcAA + Trp]) and on the 
sum of the 5 Trp competitors ([cAA])
Whereas the sum of the 5 Trp competitors Val, Leu, 
Ile, Phe and Tyr ([CAA]) is used to calculate the [Free 
Trp]/[CAA] and [Total Trp]/[CAA] ratios, that of the 
[BCAA + Trp] is required to calculate the [Phe + 
Tyr]/[BCAA + Trp] ratio. As shown in Table 3, the 
sums of [BCAA + Trp] and of the 5 [CAA] were 
dose-  dependently  decreased  from  F0  to  F3.  For 
[BCAA + Trp], significant differences were observed 
between the F0 and F2 and F0 and F3 groups at 1 
and 3 h (P = 0.036–0.001), and between F1 and F2 or 
F3 at 3 h (P = 0.05–0.001). With [CAA], all signifi-
cant differences were observed at 1–3 h. These were 
between F0 and F2, F0 and F3, F1 and F2 and F1 and 
F3 (P = 0.05–0.001). The sum of all [6CAA] is also 
shown in Table 3 for completeness.
effects of decreasing the contents  
of branched-chain amino acids on  
the [Free Trp]/[cAA], [Total Trp]/[cAA] 
and [Phe + Tyr]/[BcAA + Trp] ratios
As  shown  in  Table  3,  decreasing  the  contents  of 
BCAA from the usual level in the traditional F0 group 
met with varying degrees of success in restoring the 
above three ratios to normal baseline levels.
Thus, the [Free Trp]/[CAA] ratio was decreased 
in F0 maximally by 27% at 5 h (P = 0.013; paired 
t-test) and F1 did not correct this decrease, which 
was 26% at 2 h, rising to 39% at 4 h and remain-
ing at 32%–35% till 6 h (P = 0.034–0.004). In fact, 
none of the free Trp ratio values in the F1 group dif-
fered significantly from the corresponding values in 
the F0 group, except for that at 1 h. By contrast, no 
significant decreases in this ratio from baseline were 
observed in participants in the F2 or F3 groups at any 
time interval after formula intake. Both the F2 and 
F3 groups showed significant differences from the F0 
and F1 groups at 3–5 h (P = 0.013–0.001).
The  [Total  Trp]/[CAA]  ratio  was  consistently 
decreased from the baseline value in the traditional 
F0 group over the entire 7 h time course, with the 
decreases  at  1–5  h  (37%–45%)  being  significant 
(P  =  0.0101–0.0019).  Here  again,  F1  did  not  cor-
rect this decrease, which was also significant at all 
time  intervals  (P  =  0.05–0.0124),  except  at  1  and 
6 h. By contrast, no decreases in this ratio from base-
line were observed in participants receiving the F2 
and F3 formulae. Significant differences in this ratio 
were also observed between F1 and F3 at 2 and 3 h 
(P  =  0.071–0.038)  in  addition  to  the  differences 
between the F0 and other groups shown in Table 3.
Finally, the [Phe + Tyr]/[BCAA + Trp] ratio was 
also  significantly  decreased  from  baseline  in  the 
  traditional F0 group by 32%–47% during the first 5 h 
(P = 0.0220–0.0009). After intake of F1, no signifi-
cant decreases from baseline were observed and, in 
fact, all ratio values in F1 differed significantly from 
the corresponding values in F0 at the 1–6 h time points 
(P = 0.048–0.001). With F2, however, decreases in 
this ratio of between 15 and 40% occurred at 1–7 h, 
all of which were significant (P = 0.05–0.001). With Formulations for tryptophan or tyrosine plus phenylalanine depletion
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F3, however, no significant differences from baseline 
were observed at subsequent time intervals.
Thus, the [Free Trp]/[CAA] and [Total Trp]/[CAA] 
ratios were restored to normal in both the F2 and F3 
formulations, whereas the [Phe + Tyr]/[BCAA + Trp] 
ratio was restored in F1 and F3, but not in F2. The 
reason for the effectiveness of F1 here is due to the 
unexpectedly higher [Phe + Tyr] in this formulation 
group. It would therefore seem reasonable and pru-
dent to suggest that F3 would be the group of choice 
for maintaining normal ratios, as can be seen graphi-
cally in Fig. 1 comparing the decreased ratios in F0 
with the normalized ones in F3.
Discussion
Specificity of existing formulations for the 
ATD and ATPD tests and their loading 
counterparts
We  have  expressed  doubt  about  the  specificity  of 
the current formulations used in the acute Trp or Tyr 
depletion/loading tests to manipulate 5-HT and cat-
echolamine synthesis. Initially, it was assumed that 
the absence of Trp from the ATD formulation could 
place Tyr and Phe at a greater advantage for entry into 
the brain, resulting in enhanced central DA and/or NA 
synthesis.25 However, our subsequent studies9,10 dem-
onstrated the opposite, namely that the entry of Tyr 
and Phe into the brain is likely to be decreased due to 
the relatively larger contents of branched-chain amino 
acids (BCAA), compared with those of Tyr and Phe 
in the various formulations, which was reflected in 
the relative differences in their plasma concentration 
profiles  (for  details,  see  also3). As  a  consequence, 
the [Phe + Tyr]/[BCAA + Trp] ratio is significantly 
decreased in the ATD and more so in the ATL test, 
and  even  after  the  balanced  control  formulation.10 
This is almost certain to cause inhibition of dopamine 
synthesis. In fact, administration of a mixture of the 
3 BCAA, Val, Leu, and Ile, either alone14 or supple-
mented with Trp16,26 is known to decrease the [Phe + 
Tyr]/[BCAA] ratio and to inhibit dopamine function, 
as expressed by an increased latency to respond to the 
spatial recognition memory task (in humans) or by 
amphetamine-evoked striatal dopamine release and 
amphetamine-induced hyperactivity (in rats). A Phe + 
Tyr-depleted amino acid mixture reduces CSF levels 
of  catecholamine  metabolites  in  vervet  monkeys.27 
Other evidence for inhibition of central DA synthesis 
after Tyr depletion has already been described in the 
accompanying review.3
The need for a truly balanced  
control formulation
This need has already been emphasized.4 Most inves-
tigators using the ATD or ATL test would agree that a 
“balanced” formulation should ensure that the control 
treatment maintains baseline values without altering 
the  biochemical  or  behavioural  parameters  being 
studied, which would further enhance accurate inter-
pretation of results. As BCAA play a pivotal role in 
the ATD test, the use of a balanced control formu-
lation, rather than an amino-acid-free “neutral” pla-
cebo, is even-more important, particularly in relation 
to behavioural studies, because, apart from inducing 
a central 5-HT deficiency through Trp depletion and 
a central catecholamine deficiency through Phe and 
Tyr depletion, the BCAA have the potential to exert 
other  equally  important  metabolic  changes  which 
could also further impact behaviour (for commentary, 
see28). Thus, in the human brain, BCAA are transami-
nated by branched-chain amino acid aminotransferase 
(BCAT) to branched-chain keto acids, converting in 
the process 2-oxoglutarate to glutamate.29 BCAA are 
thus nitrogen donors for the synthesis of the excitatory 
amino acid glutamate and the inhibitory neurotrans-
mitter γ-aminobutyric acid (GABA), with Leu playing 
a particularly prominent role30–32 and it is noteworthy 
that the brain cytosolic isoenzyme of BCAT is located 
in GABAergic and glutamatergic neurons.33 Since in 
humans, the brain normally accounts for 10%–20% 
of their total body metabolism,34 a significant increase 
could be expected after loading with BCAA, as in 
the  present  work,  resulting  in  enhanced  synthesis 
of glutamate and GABA. Changes in glutamatergic 
and/or GABAergic neurotransmission are therefore 
expected under these conditions, which could impact 
on 5-HT and dopamine functions, with the potential 
to modulate behaviours associated with these cerebral 
monoamines.
The idea of improving the neutrality of the con-
trol formulation is not new, as previous attempts have 
been made. Thus, Weltzin et al (1994)17 succeeded in 
maintaining the baseline [Trp]/[CAA] ratio by increas-
ing the Trp content to 4.6 g/100 g of the traditional 
amino acid mixture. However, they did not measure Badawy et al
44  International Journal of Tryptophan Research 2010:3
the [Phe + Tyr]/[BCAA + Trp] ratio and it is almost 
certain that, with this level of Trp loading (which is 
45% of that of the ATL dose), or even without it, this 
latter ratio will have been decreased. A low dose ATD 
(25% of the normal one) has been used35 as a con-
trol, based on a previous design.36 However, although 
this low-dose mixture did not alter the [Tyr]/[CAA] 
ratio, it still decreased the [Trp]/[CAA] ratio by 42%, 
against a 92% decrease by the full dose. Surprisingly, 
the high ATD dose elevated the [Tyr]/[CAA] ratio by 
about 50%. However, interpretation of some, or all, 
of these biochemical changes is difficult because the 
subjects consumed a lunch during the test procedure. 
Still, while the use of a low-dose mixture may be use-
ful in studies examining the effects of sub-optimal 
depletion of Trp and 5-HT, it cannot be considered an 
appropriate control for the ATD test dose.
In the light of this and the preceding discussion, we 
suggest that the most appropriate approach to enhanc-
ing the specificity of these formulations is by modu-
lating the contents of the components which appear 
to be responsible for the lack of specificity, namely 
the 3 BCAA, and consider it important to begin with 
the  balanced  control  formulation.  Before  discuss-
ing the normalization of the above ratios by our modi-
fied control formulation, the pharmacokinetic data of 
the different formulations tested are worthy of brief 
comment.
Pharmacokinetic changes across  
the different control formulations
As  expected,  concentrations  of  all  three  BCAA 
showed a broadly dose-dependent decrease (Table 3) 
with decreasing order of their contents in the differ-
ent formulations. It is known37 that the two major 
BCAA-metabolising enzymes, the aminotransferase 
and  the  keto  acid  dehydrogenase,  exhibit  similar 
kinetic properties towards their substrates and their 
corresponding intermediate products with no obvi-
ous preferences. The observation (Table 3) that the 
individual concentration-time profile of each of the 3 
BCAA (i.e. Val, Leu, and Ile) followed a similar pat-
tern to each other and as their combined sum provides 
further support to this concept.
Whereas  the  observed  kinetics  of  Trp  were 
expected, those of Phe and Tyr were not, given also 
their unchanged contents in the 4 formulations. The 
higher  plasma  [Phe]  in  F1  cannot  be  explained  at 
present,  but  factors  associated  with  Phe  transport 
or Phe hydroxylase and/or Tyr hydroxylase activity 
may be involved. The similarly higher plasma [Tyr] 
in F1 may simply be a consequence of the high Phe 
being converted to Tyr by Phe hydroxylase or by Tyr 
hydroxylase,38,39 rather than an independent behav-
iour of this Tyr dose.
normalization of the free and Total  
[Trp]/[cAA] and [Phe + Tyr]/[BcAA + Trp] 
ratios by modulation of the contents  
of BcAA
As stated in the Introduction, our preferred strategy 
for normalisation of the Trp and Tyr ratios was to 
lower the contents of BCAA. In the present study, 
we examined this strategy in the control (traditional) 
formulation (F0) by reducing the contents of BCAA 
by 20% (F1), 30% (F2) and 40% (F3) and the results 
in Table 3 and Fig. 1 show that a 40% reduction of 
BCAA (in F3) led to complete normalization of all 
three ratios. We should point out that the lower [Phe + 
Tyr]/[BCAA + Trp] ratio observed after intake of the 
traditional formulation in the present work has been a 
robust and consistent finding in our previous studies9,10 
and those by others using the control formulation for 
the ATD5,6 or the ATPD11–13 test, whereas the extent 
and duration of the decrease in the [Free Trp]/[CAA] 
ratio  after  the  traditional  control  formulation  (F0) 
was somewhat variable, varying at the usual time of 
behavioural testing (5 h) between 28% (Fig. 1 in the 
present work) and 76%.9 This may be explained by 
plasma free Trp being a labile parameter easily influ-
enced by many physiological and other factors (for 
a review, see40). On the other hand, the [Total Trp]/
[CAA] ratio in the traditional formulation was more 
strongly decreased in the present work, but not in 
our previous study.10 As both the free and total [Trp]/
[CAA] ratios are important predictors of changes in 
central [5-HT]3 both ratios must be determined and a 
decrease in either justifies rectification of the formu-
lation. We particularly recommend the formulation 
with 40% less BCAA for the following reasons: (1) 
F3 normalized all 3 ratios, whereas F2 did not norma-
lise the [Phe + Tyr]/[BCAA + Trp] ratio and F1 did 
not normalise the free or total [Trp]/[CAA] ratio; (2) 
a 20% less [BCAA] in F1 did not show a pharmacoki-
netic profile different from the traditional F0 and was Formulations for tryptophan or tyrosine plus phenylalanine depletion
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associated with abnormally high [Phe + Tyr], hence 
the normalisation of the [Phe + Tyr]/[BCAA + Trp] 
ratio by the F1 formulation.
Conclusions and Comments
A possible criticism of our study is that we did not 
control for the menstrual cycle in female subjects. It 
has been reported41 that oestradiol-17β decreases the 
activity of branched-chain keto acid dehydrogenase 
complex in female rats only in the evening, by acting 
on this complex-specific kinase (BDK). While theo-
retically this may influence BCAA levels, this effect 
is more related to feeding behaviour in rats and may 
therefore be irrelevant in humans. However, it would 
be prudent in future human studies to establish if the 
phase of the menstrual cycle influences circulating 
[BCAA] and whether ATD and related tests should 
be conducted at a specific phase of this cycle.
We believe that our new control formulation con-
taining 40% less BCAA should be adopted as the 
truly balanced control in studies employing the ATD 
and ATPD tests and their loading counterparts and 
should like to name it the acute balanced-control test 
(ABCT) formulation. Using a single unified control 
formulation for manipulation of Trp and Tyr plus Phe 
should contribute to uniformity in studies with the 
control condition and allow a better control reference 
in studies of combined or individual 5-HT, DA and 
NA depletion or loading. Investigators should no lon-
ger ignore the decrease in the [Phe + Tyr]/[BCAA + 
Trp] ratio in the ATD, ATL, or balanced-control for-
mulations, nor those in the [Trp]/[CAA] ratios in 
the latter formulation and the ATPD or loading tests 
and their likely impacts on behaviour, particularly in 
patient populations. An important question arising 
from this work is whether the decreased content of 
BCAA in the proposed new ABCT formulation can 
also ensure that only the desired changes in ratios 
occur during the ATD, ATL, ATPD and ATPL tests. 
With the ATD and ATL tests, a 40% less BCAA for-
mulation should result respectively in the expected 
decrease or increase in the [Trp]/[CAA] ratios. In 
fact, on theoretical grounds,10 changing the content 
of BCAA should make little difference to the Trp 
ratios in the ATD test, whereas the 40% decrease 
can  only  enhance  the  desirable  increases  associ-
ated with ATL. As regards the [Phe + Tyr]/[BCAA + 
Trp] ratio, some provisional calculations were made 
from the data in Table 3 of the present work and 
from those reported by us previously9 for the 50 g 
depletion and loading formulations. Calculation of 
this  ratio  revealed  small  fluctuations  of  between 
+7% and –15% from baseline in the ATD test and 
a  near  normal  ratio  around  about  0.2  during  the 
entire 7 h time course of the ATL test. With regard 
to the ATPD, a major decrease in the [Phe + Tyr]/
[BCAA + Trp] ratio is guaranteed on the same theo-
retical grounds as for ATD, and calculations from 
previously reported data by the Canadian group11 
derived from the same traditional formulation as in 
the present work, but without Phe or Tyr, show that 
the free and total [Trp]/[CAA] ratios are moderately 
decreased (by 15 and 27% respectively); such mod-
est decreases can easily be reversed by using our F3 
with 40% less BCAA. The reason why the above 
decreases in the [Trp]/[CAA] ratios are moderate, in 
comparison with the greater decreases in other stud-
ies by the Oxford group, is almost certainly because 
the  former  group11  used  less  BCAA  (29%  of  the 
total dose) than did the above group (47%–48% of 
the total dose) (see, e.g. refs2,12). As for the ATPL, 
while the increase in the [Phe + Tyr]/[BCAA + Trp] 
is also guaranteed with our F3 formulation, it is dif-
ficult to predict with greater certainty whether the 
free and total [Trp]/[CAA] ratios will remain unal-
tered or undergo a decrease. Perhaps the contents of 
Phe and Tyr in the ATPL formulation need not be as 
high as could be assumed (perhaps only moderately 
higher  than  in  the  control  formulation),  specially 
as the lower content of BCAA should ensure that 
the [Phe + Tyr]/[BCAA + Trp] ratio will not be low. 
Another reason for having a moderately higher Phe 
and Tyr content in the ATPL formulation is to ensure 
that brain [Tyr] is not elevated excessively and thus 
avoid  the  substrate  inhibition  of Tyr  hydroxylase 
activity.42 Confirmation of all these provisional val-
ues and predictions will clearly require further work 
with the ATD, ATL, ATPD and ATPL test formula-
tions comparing the traditional F0 with the 40% less 
BCAA F3 formulation under the same experimen-
tal  conditions. We  hope  that  by  proposing  a  new 
  balanced control formulation associated with normal 
Trp and Tyr ratios, we have made a useful contribu-
tion to the acute depletion and loading methodology 
that will serve to enhance interpretation of behav-
ioural and biochemical data in future research.Badawy et al
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